An APP gene test during a dementia second opinion checks for an inherited change that can cause early-onset Alzheimer's. It fits only a narrow group, so the visit should settle cost, coverage rules, and referral reasons. APP is a gene tied to inherited Alzheimer's that often starts before age 65. A second opinion can clarify whether family pattern, diagnosis, and insurance rules make testing useful now.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who is APP testing actually for?
- What will the referral lab test?
- How much does it cost and will insurance pay?
- What counseling and privacy steps come first?
Who is APP testing actually for?
APP is one of only three genes — APP, PSEN1, PSEN2 — where an altered copy makes Alzheimer's likely before age 65, according to the National Institute on Aging fact sheet. That deterministic pattern differs from risk genes like APOE, which raise risk without determining disease. Early-onset disease is only 3%-5% of all Alzheimer's cases, so disease-causing APP variants are rare overall.
Within early-onset familial cases, APP accounts for about 10%-15% and PSEN1 for 20%-70%. In practice, testing matters most with multiple relatives affected young, an autosomal-dominant pattern, or a known family mutation. A second opinion can weigh that history against other causes of young-onset decline.
What will the referral lab test?
Clinical labs offer APP testing as targeted sequencing or as part of a broader dementia panel. One hospital panel covers 21 genes including APP, PSEN1, PSEN2, APOE, MAPT and GRN, according to the OHSU Knight Diagnostic Laboratories test page.
That page lists family history of dementia before age 60, confirmation of a clinical diagnosis, and carrier testing as reasons for referral. Bring exact diagnoses, relationship to you, ages at onset, and any prior genetic reports. Ask the second-opinion doctor:.
- targeted APP testing or a full dementia panel for this history
- what a positive, negative, or uncertain result would change
- which lab will run it and what sample it needs
How much does it cost and will insurance pay?
Commercial hereditary testing has been marketed with non-insurance self-pay pricing around $475 per indication, reported by Inside Precision Medicine. Your price may differ, so ask the referral lab for its cash price, CPT codes, and pre-authorization needs. One major insurer policy covers APP, PSEN1 and PSEN2 testing as medically necessary only when results will inform reproductive decisions plus autosomal-dominant history, a known familial mutation, or suspected early-onset disease with unknown history, described in the Healthy Blue medical policy.
Other uses are excluded under that policy. Ask for the coverage check in writing before blood is drawn. Confirm medical-necessity wording, prior approval, and what you owe if the claim is denied.
What counseling and privacy steps come first?
Genetic counseling is often required before and after familial Alzheimer testing. It covers treatment limits, family risk, reproductive choices, and emotional effects for relatives. Federal GINA protection bars health-insurer and employer use of genetic information.
It does not extend to life, disability, or long-term-care insurance. Ask about that gap before testing, especially if you plan to apply for those policies. Decide who in the family should hear results and when.
